$CVKD
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Healthcare
Sector
Biotechnology
Industry
Quang X. Pham
CEO
4
Employees
$3.17
Current Price
$12.94M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 7 | $109,281.12 | 34,126 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 20 | $333,575.17 | 87,726 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 22 | $388,290.37 | 97,500 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| May 11, 2026 | Pham Quang X Director | Sale | 6,476 | $5.76 | $37,301.76 | View Details |
| May 22, 2026 | Pham Quang X Director | Sale | 1,165 | $5.69 | $6,628.85 | View Details |
23 more transactions available โ create a free account to see 12 months of history | ||||||
Showing 21โ22 of 22 transactions
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
5 more earnings records available โ create a free account to see 12 months of history